CAMBRIDGE, Mass.--(BUSINESS WIRE)--Surface Oncology, an immuno-oncology company developing next-generation antibody therapies that target the tumor microenvironment, today announced the expansion of the company’s board of directors with the addition of three new members. Elliott Sigal, M.D., Ph.D., Geoff McDonough, M.D., and Laurie Stelzer will work with the other members of the Surface board of directors to guide the company as it advances its broad portfolio of immuno-oncology therapies.
“The Surface team is delighted to welcome Elliott, Geoff and Laurie to our board of directors,” said Jeff Goater, chief executive officer of Surface Oncology. “They are accomplished biopharma leaders and their considerable experience will be invaluable as we continue our evolution into a clinical stage company.”
Dr. Sigal is a Venture Partner and Senior Advisor at NEA Ventures and has been a member of Surface Oncology’s Scientific Advisory Board since 2014. Previously, he served as chief scientific officer and president of R&D for Bristol-Myers Squibb (BMS) where 14 new medicines were brought to market under his leadership. Among these was the first checkpoint inhibitor, Yervoy, which helped establish BMS as a leader in immuno-oncology. In 2012, Dr. Sigal was named the best R&D chief in the pharmaceutical industry by Scrip Intelligence. He is co-chair of Amgen’s Scientific Advisory Network and a member of the board of directors of Adaptimmune, Spark Therapeutics, and the Melanoma Research Alliance.
Dr. McDonough is president and CEO of Generation Bio which he helped launch earlier this year. Dr. McDonough previously served as president and CEO of Swedish Orphan Biovitrum AB (Sobi) from 2011 until 2017, where he led the expansion of the company’s portfolio into the rare disease space. He also held a variety of senior roles at Genzyme Corporation, including president of Genzyme Europe where he was responsible for overseeing operations in 55 countries and a portfolio of 15 products. Dr. McDonough earned his medical degree from Harvard Medical School and completed his residency training in internal medicine and pediatrics at Massachusetts General Hospital and Boston Children's Hospital.
Ms. Stelzer is chief financial officer at Halozyme Therapeutics. Prior to Halozyme, she held several roles at Shire, Inc. including senior vice president of finance supporting R&D, Technical Operations and M&A, CFO for the Regenerative Medicine Division, and head of investor relations. She also held positions of increasing responsibility for 15 years at Amgen, Inc. including interim treasurer, head of emerging markets expansion, executive director of global commercial finance and head of global accounting. Ms. Stelzer received her MBA from the Anderson School at the University of California, Los Angeles.
ABOUT SURFACE ONCOLOGY
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD47 and CD73. Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. The company has a pipeline of seven novel immunotherapies and a strategic collaboration with Novartis focused on up to four next-generation cancer immunotherapies. Headquartered in Cambridge, Mass., Surface was founded by Atlas Venture. For more information, please visit www.surfaceoncology.com.